NOTICE REGARDING THE OFFERING RESULTS OF 4th TRANCHE OF UAB “KVARTALAS” BONDS AND AMENDED FINAL TERMS
Globenewswire· 2025-10-03 07:00
UAB "Kvartalas" aimed to raise 5 million euros during the offering of the fourth tranche of bonds to finance the development of the "Sąvaržėlė" business centre on Konstitucijos ave. in Vilnius. The offering began on 30 September 2025 and was initially scheduled to run until 10 October. However, considering the high demand for Bonds in the previous tranches, in this tranche, the Issuer had the right to shorten the offering period once it determined that sufficient investor demand has been reached, to ensure ...
Fingerprint Cards AB (publ) completes third IP monetization and licensing transaction in 11 months, with a new PixArt Imaging Inc. deal signed for SEK 19 million upfront plus royalty potential
Globenewswire· 2025-10-03 06:35
Fingerprint Cards AB (FPC) today announced its third IP monetization and licensing transaction in the past 11 months, entering into a commercialization and licensing arrangement with PixArt Imaging Inc. (“PixArt”). Under the agreement, FPC will transfer certain fingerprint sensor technology assets and grant a license to certain patents and algorithm software for use in PC applications. FPC will receive USD 2.0 million (approximately SEK 19 million) in upfront consideration and retains the right to receive r ...
Karolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor
Globenewswire· 2025-10-03 06:30
STOCKHOLM, SWEDEN – October 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has been granted a patent in the US protecting its drug candidate tafoxiparin for its main target indication, priming of labor. The patent will serve as a key asset as Dilafor advances into phase 3 clinical development of tafoxiparin. The United States Patent and Trademark Office (USPTO) has granted Dilafor a US patent for the use of its proprietary development compound ...
Felice Capasso of Norway Crowned World’s Best Bartender 2025 at the prestigious World Class Global Finals
Globenewswire· 2025-10-03 06:15
In its 16th year, Diageo World Class saw bartenders from 51 countries take to the stage for the world’s most coveted bartending title TORONTO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Felice Capasso from Norway has been awarded the career defining title of World Class Global Bartender of the Year 2025 at one of the world’s leading cocktail competitions, celebrated in Toronto this year. Competing against finalists from 51 markets around the world, spanning six continents, Felice was named as the ultimate winner by ...
Invitation to HMS Networks’ third quarter conference call 2025
Globenewswire· 2025-10-03 06:02
HMS Networks AB (publ) will release its third quarter report of 2025 on Tuesday October 21st, 2025, at 07.30 AM CEST. On the same day, at 09.00 AM CEST, President and CEO Staffan Dahlström and CFO Joakim Nideborn present the report in a conference call for press and analysts. The presentation is in English and can be followed live via telephone or web. Slides used in the presentation will be made available on HMS’ website prior to the telephone conference. If you wish to participate via webcast, please use ...
AS Tallink Grupp Statistics for September and the Third Quarter of 2025
Globenewswire· 2025-10-03 06:00
In September 2025 AS Tallink Grupp transported 387,482 passengers, which is a 4.1% decrease compared to September 2024. The number of cargo units decreased by 8.2% to 21,269 units and the number of passenger vehicles was down by 5.9% amounting to 55,973 units compared to the same period a year ago. In the third quarter of the year (July–September) AS Tallink Grupp transported 1,766,335 passengers, which is a 3.0% increase compared to the previous year. The number of transported cargo units decreased by 9.8% ...
AKVA group ASA: New land-based RAS contract signed
Globenewswire· 2025-10-03 06:00
AKVA group ASA (“AKVA”) hereby announces that it has been awarded a RAS contract from Tytlandsvik Aqua AS for the delivery of two post smolt modules at Tytlandsvik, Rogaland. Each module will provide a production capacity of 1,500 tonnes. AKVA is scheduled to commence design and engineering work in the fourth quarter of 2025, and the contract has an estimated value of NOK 220 mill. AKVA has delivered all previous post smolt modules to Tytlandsvik, and this last award further strengthens the long-standing pa ...
Appointment of Marc Le Bozec as Interim CEO
Globenewswire· 2025-10-03 06:00
Appointment of Marc Le Bozec as Interim CEO Nantes, October 3, 2025, 8:00 a.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) announces the termination of the position as chief executive officer of Mr. Nicolas Poirier and the appointment of Mr. Marc Le Bozec as interim CEO, as decided yesterday by the Board of Directors. The Board of Directors has commenced a formal search for a new permanent Chief Executive Officer. The Board of Directors has empowered Marc Le Bozec to lead a strategic e ...
Sampo plc’s share buybacks 2 October 2025
Globenewswire· 2025-10-03 05:30
Sampo plc, stock exchange release, 3 October 2025 at 8:30 am EEST Sampo plc’s share buybacks 2 October 2025 On 2 October 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code) 5,2529.62AQEU 119,2729.65CEUX 42,5019.66TQEX 173,0269.64<td style="width:5cm ...
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
Globenewswire· 2025-10-03 05:05
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC*3 Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecen ...